Travoprost monotherapy effective for POAG

Article

Travoprost monotherapy has demonstrated long-term 24-hour efficacy for the treatment of primary open-angle glaucoma (POAG).

Travoprost monotherapy has demonstrated long-term 24-hour efficacy for the treatment of primary open-angle glaucoma (POAG).

In a 5-year study reported in the Journal of Glaucoma, 36 previously untreated POAG patients received topical travoprost 0.004% eye-drops preserved with benzalkonium chloride (Travatan, Alcon Laboratories), once in the evening in both eyes.

All patients received a pre-treatment 24-hour IOP evaluation, followed by a series of 5 follow-up 24-hour evaluations at 12-month intervals throughout the trial.

In the 34 patients who completed the study, the travoprost monotherapy reduced the mean 24-hour IOP from 23.4 (±1.7) mmHg at baseline to the following:

  • 16.8 (±2.4) mmHg at the 1-year assessment, a 28.4% decrease in IOP from baseline.
  • 16.8 (±2.5) mmHg at the 2-year assessment (-28.1% from baseline)
  • 16.8 (±2.4) mmHg at the 3-year assessment (-28.5% from baseline)

  • 16.7 (±2.5) mmHg at the 4-year assessment (-28.6% from baseline)
  • 16.9 (±2.4) mmHg at the 5-year assessment (-27.8% from baseline)

To read an abstract of the study, click here.

Newsletter

Get the essential updates shaping the future of pharma manufacturing and compliance—subscribe today to Pharmaceutical Technology and never miss a breakthrough.

Recent Videos
Jay Chhablani, MD, shares late-breaking data from the ArMaDa trial, investigating gene therapy for Geographic Atrophy and dry age-related macular degeneration, at EURETINA
Editorial advisory board member Alexandra Miere, MD, PhD, speaks about the ACTOR and HERMES studies at the 2025 European Society of Retina Specialists (EURETINA) Congress
María Berrocal, MD, speaks about the Vit-Buckle Society symposium hosted at the 2025 European Society of Retina Specialists (EURETINA) annual meeting
© 2025 MJH Life Sciences

All rights reserved.